Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting

Andrea K. Miyahira, Sophia C. Kamran, Tamara Jamaspishvili, Catherine H. Marshall, Kara N. Maxwell, Abhijit Parolia, Nicholas A. Zorko, Kenneth J. Pienta, Howard R. Soule

Research output: Contribution to journalArticlepeer-review


Introduction: The 2023 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023. Methods: The 2023 marked the 10th Annual CHPCA Meeting, a discussion-oriented scientific think-tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions. Results: The central topic areas covered at the meeting included: targeting transcription factor neo-enhancesomes in cancer, AR as a pro-differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence-driven precision medicine. Discussion: This article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.

Original languageEnglish (US)
Pages (from-to)993-1015
Number of pages23
Issue number11
StateAccepted/In press - 2024

Bibliographical note

Publisher Copyright:
© 2024 Wiley Periodicals LLC.


  • biomarkers
  • cancer disparities
  • theranostics
  • therapeutics
  • tumor biology


Dive into the research topics of 'Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting'. Together they form a unique fingerprint.

Cite this